Developer docs
API playgroundTry for free, no card

Search company profiles

Biofidelity

Full company profile

uuid000481g

Namestring
Biofidelity
Legal namestring
Biofidelity Ltd
Websiteurl
biofidelity.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Biofidelity is a Cambridge, UK-based molecular diagnostics company founded in 2019 that has developed a proprietary pyrophosphorolysis-based detection technology for genomic biomarker analysis. The company's product portfolio centers on the Aspyre platform, which detects 114 variants across 11 genes relevant to non-small cell lung cancer (NSCLC) using a four-step workflow that runs on existing qPCR instruments, eliminating the requirement for next-generation sequencing (NGS) infrastructure. The platform achieves 100% specificity, rescues 98% of samples that fail NGS quality control, and delivers next-day results versus the typical 21-day NGS turnaround. Aspyre is commercialized through two channels: a CLIA-certified laboratory-developed test (Aspyre Clinical Test for Lung) offered through Biofidelity's Morrisville, NC laboratory, and research-use-only reagents (Aspyre Lung Reagents) sold to laboratories for decentralized testing. A complementary technology, Enspyre, provides NGS target enrichment that removes up to 99% of background DNA to enable 100x efficiency improvement in sequencing applications including minimal residual disease detection.

The company operates a sales-led go-to-market targeting three primary customer segments: oncologists and thoracic cancer specialists using clinical tests to guide targeted therapy decisions, pathologists and laboratory directors conducting genomic biomarker testing, and biopharmaceutical companies using reagents for clinical trial patient screening. Strategic channel partnerships with CellCarta (global clinical trial exclusive rights) and Fidelis Sustainability Distribution (US VA Medical Centers and military healthcare) extend reach into enterprise and government accounts. Revenue is generated through clinical laboratory testing services, RUO reagent sales, and licensing of Enspyre technology to pharmaceutical companies, CROs, and precision medicine developers. The company has raised approximately $60 million in total funding since inception across seed, Series A, Series A+, and strategic financing rounds, with Octopus Ventures and Agilent Technologies as primary investors. Aspyre and Enspyre core technology is protected by patents granted in the United States, Europe, and China. Biofidelity maintains certifications including CLIA, CAP accreditation, ISO 13485:2016, and clinical laboratory licenses in multiple US states.

Short descriptiontext

Biofidelity is a molecular diagnostics company that develops pyrophosphorolysis-based Aspyre and Enspyre technologies for rapid, decentralized genomic biomarker testing in cancer, serving oncologists, pathologists, clinical laboratories, and biopharmaceutical companies through CLIA-certified testing services and research-use reagents.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular diagnostics, genomic biomarker testing, cancer diagnostics, NGS enrichment technology, PCR-based assays
Industry2 codes
PRIMARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
SECONDARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Molecular Diagnostics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Clinical Laboratory Testing Services
TypeOne Time License
Description

Aspyre Clinical Test for Lung is offered as a laboratory-developed test through Biofidelity's CLIA-certified laboratory in Morrisville, NC. Healthcare providers submit tissue or blood samples for genomic biomarker analysis, with results returned within 2 days for treatment decision-making.

2Research Use Only Reagent Sales
TypeOne Time License
Description

Aspyre Lung Reagents are sold to research laboratories and biopharma companies for use in NSCLC research. The reagents enable decentralized genomic testing on existing qPCR instrumentation without requiring NGS infrastructure.

3Licensing and Partnership Revenue
TypeLicensing Royalties
Description

Biofidelity licenses its Enspyre technology to pharmaceutical companies, CROs, and precision medicine developers. The company is pursuing an 'Intel Inside' approach for Enspyre commercialization through partnerships.

Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Pricing details1 tier
1Aspyre Clinical Test for Lung - Laboratory testing service
ModelOtherBilling cadencePay-as-you-go
Notes

Quote-based pricing for clinical testing services. Healthcare providers submit samples for biomarker analysis with results returned within 2 days. Specific pricing not publicly disclosed.

GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1Aspyre®
Description

Advanced molecular technology platform for biomarker detection in cancer, designed to simplify genomic analysis and run on existing PCR instruments.

+3 more records
Core offering1 text field

Biofidelity develops proprietary pyrophosphorolysis-based molecular diagnostic technology sold under the Aspyre® and Enspyre® brands. The company sells research-use reagents (Aspyre Lung Reagents) to laboratories and biopharma companies, operates a CLIA-certified laboratory providing the Aspyre Clinical Test for Lung (a laboratory-developed test for NSCLC biomarker detection from tissue or blood), and licenses Enspyre NGS target enrichment technology to pharma, CROs, and precision medicine developers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 98% of samples that fail NGS QC are rescued by Aspyre
+4 more records
Product overview1 text field

Biofidelity offers a unified portfolio of genomic testing products centered on two innovative technologies: Aspyre® and Enspyre®. Aspyre® provides a simplified alternative to NGS for biomarker detection, available as both a clinical laboratory test (Aspyre® Clinical Test for Lung) and research reagents (Aspyre® Lung Reagents). Enspyre® is a complementary NGS enrichment technology that dramatically improves sequencing efficiency. Together, these products serve the complete cancer patient journey from early detection to treatment selection to minimal residual disease monitoring.

Product and service4 records
1Aspyre Clinical Test for Lung
CategoryClinical Genomic Testing Services
Description

A CLIA-certified laboratory-developed test providing next-day biomarker results for non-small cell lung cancer (NSCLC) patients. Analyzes DNA and RNA from tissue or blood samples, detecting 114 variants across 11 genes including SNVs/Indels, RNA fusions, and MET exon 14 skipping. Designed for healthcare providers and oncologists requiring rapid treatment decision support.

2Aspyre Lung Reagents
CategoryResearch Reagents
Description

Research use only (RUO) reagent kit enabling decentralized NSCLC biomarker testing on existing qPCR platforms. Uses a 4-step workflow to analyze 114 variants across 11 genes including DNA SNVs/Indels and RNA fusions. Sold to research laboratories and biopharma companies.

3Enspyre NGS Enrichment Technology
CategoryTechnology Licensing
Description

Novel target enrichment technology that removes more than 99% of uninformative background DNA prior to sequencing, enabling 100x improvement in NGS efficiency. Enables detection of thousands of variants at less than 3% of standard sequencing depth. Licensed to pharmaceutical companies, CROs, and precision medicine developers for applications including minimal residual disease (MRD) detection.

4Aspyre Technology Platform
CategoryDiagnostic Technology Platform
Description

Molecular diagnostic platform based on pyrophosphorolysis chemistry that runs on existing qPCR instruments with a 4-step workflow and turnkey data analysis. Detects 114 variants across 11 genes with 100% specificity and rescues 98% of samples that fail NGS quality control.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-19
Description

Expanded multi-year global strategic partnership granting CellCarta exclusive rights to offer Aspyre Lung assay in clinical trial settings globally. CellCarta serves as the exclusive clinical trial partner and will deploy the assay across global trials, with potential for future collaboration on Biofidelity's minimal residual disease technology. The partnership enables faster, more cost-effective biomarker testing compared to traditional NGS methods.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-01-24
Description

Distribution partnership to make Aspyre Lung available to VA Medical Centers and active military institutions across the United States. Fidelis enables access to government healthcare customers for rapid precision genomic testing.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-09
Description

Initial strategic partnership agreement to utilize Aspyre Lung in global clinical trials. CellCarta to set up and validate Aspyre Lung in European laboratories first, followed by US-based laboratories, with non-exclusive rights for clinical trials globally.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Commercial-stage molecular diagnostics company focused on cancer detection (Cologuard, Oncotype DX). Comparable to Biofidelity as a scaled molecular diagnostics franchise leveraging clinical lab infrastructure and proprietary assays for oncology decision-making.

TypeDirect peer
Description

Specialized oncology-focused clinical laboratory services company offering molecular and genetic testing for cancer. Directly comparable to Biofidelity's CLIA lab service business serving oncologists and pathologists with biomarker profiling.

TypeBroad incumbent
Description

Industry-leading NGS-based comprehensive genomic profiling provider for solid tumors, owned by Roche. Comparable as the dominant incumbent in cancer genomic profiling against which Aspyre competes on speed and cost.

4Tempus
TypeBroad incumbent
Description

AI-enabled precision medicine company offering NGS-based molecular profiling, clinical trial matching, and data analytics for oncology. Comparable as a broad-scale NGS-based competitor targeting oncologists with comprehensive genomic profiling.

TypeDirect peer
Description

Leading liquid biopsy and precision oncology company (Guardant360, Shield) focused on NGS-based blood-based cancer testing. Comparable to Biofidelity's liquid biopsy work on NSCLC plasma samples and as a developer of decentralized cancer biomarker assays.

TypeDirect peer
Description

Molecular science and technology company offering comprehensive molecular profiling (MI Profile, MI Cancer Seek) for oncology. Comparable as a competing molecular profiling service for solid tumors targeting oncologists and biopharma trial sponsors.

TypeDirect peer
Description

Cancer genomics company offering NGS-based tumor profiling (NeXT Personal) and MRD solutions. Comparable to Biofidelity across both tumor profiling and emerging MRD detection, with overlap in NSCLC biomarker testing.

TypeDirect peer
Description

Cell-free DNA testing company with Signatera tumor-informed MRD assay and oncology liquid biopsy products. Comparable to Biofidelity on decentralized molecular oncology testing and overlapping MRD roadmap via Enspyre.

TypeEmerging player
Description

Acquired by Agilent Technologies in 2021, Resolution Bioscience develops NGS-based liquid biopsy kits for cancer. Highly comparable as a technology platform for decentralized cancer biomarker testing — and notably an Agilent portfolio company, creating a strategic adjacency with Biofidelity's own Agilent-backed strategy.

10Oncocyte
TypeEmerging player
Description

Molecular diagnostics company developing and commercializing tests for transplant monitoring and oncology (DetermaRx, DetermaIO). Comparable as a small-to-mid-cap precision oncology diagnostics company pursuing similar hospital and biopharma channels.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Biofidelity

Molecular Diagnosticsbiofidelity.com

Biofidelity is a molecular diagnostics company that develops pyrophosphorolysis-based Aspyre and Enspyre technologies for rapid, decentralized genomic biomarker testing in cancer, serving oncologists, pathologists, clinical laboratories, and biopharmaceutical companies through CLIA-certified testing services and research-use reagents.

What Biofidelity does

Biofidelity is a Cambridge, UK-based molecular diagnostics company founded in 2019 that has developed a proprietary pyrophosphorolysis-based detection technology for genomic biomarker analysis. The company's product portfolio centers on the Aspyre platform, which detects 114 variants across 11 genes relevant to non-small cell lung cancer (NSCLC) using a four-step workflow that runs on existing qPCR instruments, eliminating the requirement for next-generation sequencing (NGS) infrastructure. The platform achieves 100% specificity, rescues 98% of samples that fail NGS quality control, and delivers next-day results versus the typical 21-day NGS turnaround. Aspyre is commercialized through two channels: a CLIA-certified laboratory-developed test (Aspyre Clinical Test for Lung) offered through Biofidelity's Morrisville, NC laboratory, and research-use-only reagents (Aspyre Lung Reagents) sold to laboratories for decentralized testing. A complementary technology, Enspyre, provides NGS target enrichment that removes up to 99% of background DNA to enable 100x efficiency improvement in sequencing applications including minimal residual disease detection.

The company operates a sales-led go-to-market targeting three primary customer segments: oncologists and thoracic cancer specialists using clinical tests to guide targeted therapy decisions, pathologists and laboratory directors conducting genomic biomarker testing, and biopharmaceutical companies using reagents for clinical trial patient screening. Strategic channel partnerships with CellCarta (global clinical trial exclusive rights) and Fidelis Sustainability Distribution (US VA Medical Centers and military healthcare) extend reach into enterprise and government accounts. Revenue is generated through clinical laboratory testing services, RUO reagent sales, and licensing of Enspyre technology to pharmaceutical companies, CROs, and precision medicine developers. The company has raised approximately $60 million in total funding since inception across seed, Series A, Series A+, and strategic financing rounds, with Octopus Ventures and Agilent Technologies as primary investors. Aspyre and Enspyre core technology is protected by patents granted in the United States, Europe, and China. Biofidelity maintains certifications including CLIA, CAP accreditation, ISO 13485:2016, and clinical laboratory licenses in multiple US states.

Biofidelity firmographics

Firmographics
Name
Biofidelity
Legal name
Biofidelity Ltd
Website
https://biofidelity.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Biofidelity is a molecular diagnostics company that develops pyrophosphorolysis-based Aspyre and Enspyre technologies for rapid, decentralized genomic biomarker testing in cancer, serving oncologists, pathologists, clinical laboratories, and biopharmaceutical companies through CLIA-certified testing services and research-use reagents.
Ownership category
akta.pro rank

Biofidelity industry classification

Industry
Product category
Molecular Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
SECONDARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)

Keywords

  • Molecular diagnostics
  • Genomic biomarker testing
  • Cancer diagnostics
  • NGS enrichment technology
  • PCR-based assays

Where Biofidelity is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Biofidelity business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Clinical Laboratory Testing Services: Aspyre Clinical Test for Lung is offered as a laboratory-developed test through Biofidelity's CLIA-certified laboratory in Morrisville, NC. Healthcare providers submit tissue or blood samples for genomic biomarker analysis, with results returned within 2 days for treatment decision-making.
  2. Research Use Only Reagent Sales: Aspyre Lung Reagents are sold to research laboratories and biopharma companies for use in NSCLC research. The reagents enable decentralized genomic testing on existing qPCR instrumentation without requiring NGS infrastructure.
  3. Licensing and Partnership Revenue: Biofidelity licenses its Enspyre technology to pharmaceutical companies, CROs, and precision medicine developers. The company is pursuing an 'Intel Inside' approach for Enspyre commercialization through partnerships.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goAspyre Clinical Test for Lung - Laboratory testing service

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Biofidelity product offering

Product offering

Core offering

Biofidelity develops proprietary pyrophosphorolysis-based molecular diagnostic technology sold under the Aspyre® and Enspyre® brands. The company sells research-use reagents (Aspyre Lung Reagents) to laboratories and biopharma companies, operates a CLIA-certified laboratory providing the Aspyre Clinical Test for Lung (a laboratory-developed test for NSCLC biomarker detection from tissue or blood), and licenses Enspyre NGS target enrichment technology to pharma, CROs, and precision medicine developers.

Product overview

Biofidelity offers a unified portfolio of genomic testing products centered on two innovative technologies: Aspyre® and Enspyre®. Aspyre® provides a simplified alternative to NGS for biomarker detection, available as both a clinical laboratory test (Aspyre® Clinical Test for Lung) and research reagents (Aspyre® Lung Reagents). Enspyre® is a complementary NGS enrichment technology that dramatically improves sequencing efficiency. Together, these products serve the complete cancer patient journey from early detection to treatment selection to minimal residual disease monitoring.

Differentiator

Problem solved

Functional benefit

Brands

  • Aspyre®: Advanced molecular technology platform for biomarker detection in cancer, designed to simplify genomic analysis and run on existing PCR instruments.
  • Aspyre® Lung
  • Enspyre®
  • Aspyre® Clinical Test for Lung

Products and services

  • Aspyre Clinical Test for Lung A CLIA-certified laboratory-developed test providing next-day biomarker results for non-small cell lung cancer (NSCLC) patients. Analyzes DNA and RNA from tissue or blood samples, detecting 114 variants across 11 genes including SNVs/Indels, RNA fusions, and MET exon 14 skipping. Designed for healthcare providers and oncologists requiring rapid treatment decision support.
  • Aspyre Lung Reagents Research use only (RUO) reagent kit enabling decentralized NSCLC biomarker testing on existing qPCR platforms. Uses a 4-step workflow to analyze 114 variants across 11 genes including DNA SNVs/Indels and RNA fusions. Sold to research laboratories and biopharma companies.
  • Enspyre NGS Enrichment Technology Novel target enrichment technology that removes more than 99% of uninformative background DNA prior to sequencing, enabling 100x improvement in NGS efficiency. Enables detection of thousands of variants at less than 3% of standard sequencing depth. Licensed to pharmaceutical companies, CROs, and precision medicine developers for applications including minimal residual disease (MRD) detection.
  • Aspyre Technology Platform Molecular diagnostic platform based on pyrophosphorolysis chemistry that runs on existing qPCR instruments with a 4-step workflow and turnkey data analysis. Detects 114 variants across 11 genes with 100% specificity and rescues 98% of samples that fail NGS quality control.

Quantifiable outcome

  • 98% of samples that fail NGS QC are rescued by Aspyre
  • +4 more outcomes

Companies that use Biofidelity

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles5 records

Biofidelity technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Biofidelity partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • CellCartacoreStrategic or Co-development Partner · 19 March 2026Expanded multi-year global strategic partnership granting CellCarta exclusive rights to offer Aspyre Lung assay in clinical trial settings globally. CellCarta serves as the exclusive clinical trial partner and will deploy the assay across global trials, with potential for future collaboration on Biofidelity's minimal residual disease technology. The partnership enables faster, more cost-effective biomarker testing compared to traditional NGS methods.
  • Fidelis Sustainability DistributioncoreChannel Partner/ Reseller/ Distributor · 24 January 2024Distribution partnership to make Aspyre Lung available to VA Medical Centers and active military institutions across the United States. Fidelis enables access to government healthcare customers for rapid precision genomic testing.
  • CellCartacoreStrategic or Co-development Partner · 9 January 2024Initial strategic partnership agreement to utilize Aspyre Lung in global clinical trials. CellCarta to set up and validate Aspyre Lung in European laboratories first, followed by US-based laboratories, with non-exclusive rights for clinical trials globally.

Scale indicators6 records

Recent moves9 records

Expansion highlights6 records

Biofidelity competitors and assessment

Company assessment

Direct peers

  • Exact Sciences: Commercial-stage molecular diagnostics company focused on cancer detection (Cologuard, Oncotype DX). Comparable to Biofidelity as a scaled molecular diagnostics franchise leveraging clinical lab infrastructure and proprietary assays for oncology decision-making.
  • NeoGenomics: Specialized oncology-focused clinical laboratory services company offering molecular and genetic testing for cancer. Directly comparable to Biofidelity's CLIA lab service business serving oncologists and pathologists with biomarker profiling.
  • Guardant Health: Leading liquid biopsy and precision oncology company (Guardant360, Shield) focused on NGS-based blood-based cancer testing. Comparable to Biofidelity's liquid biopsy work on NSCLC plasma samples and as a developer of decentralized cancer biomarker assays.
  • Caris Life Sciences: Molecular science and technology company offering comprehensive molecular profiling (MI Profile, MI Cancer Seek) for oncology. Comparable as a competing molecular profiling service for solid tumors targeting oncologists and biopharma trial sponsors.
  • Personalis: Cancer genomics company offering NGS-based tumor profiling (NeXT Personal) and MRD solutions. Comparable to Biofidelity across both tumor profiling and emerging MRD detection, with overlap in NSCLC biomarker testing.
  • Natera: Cell-free DNA testing company with Signatera tumor-informed MRD assay and oncology liquid biopsy products. Comparable to Biofidelity on decentralized molecular oncology testing and overlapping MRD roadmap via Enspyre.

Broad incumbents

  • Foundation Medicine (Roche): Industry-leading NGS-based comprehensive genomic profiling provider for solid tumors, owned by Roche. Comparable as the dominant incumbent in cancer genomic profiling against which Aspyre competes on speed and cost.
  • Tempus: AI-enabled precision medicine company offering NGS-based molecular profiling, clinical trial matching, and data analytics for oncology. Comparable as a broad-scale NGS-based competitor targeting oncologists with comprehensive genomic profiling.

Emerging players

  • Resolution Bioscience (Agilent): Acquired by Agilent Technologies in 2021, Resolution Bioscience develops NGS-based liquid biopsy kits for cancer. Highly comparable as a technology platform for decentralized cancer biomarker testing — and notably an Agilent portfolio company, creating a strategic adjacency with Biofidelity's own Agilent-backed strategy.
  • Oncocyte: Molecular diagnostics company developing and commercializing tests for transplant monitoring and oncology (DetermaRx, DetermaIO). Comparable as a small-to-mid-cap precision oncology diagnostics company pursuing similar hospital and biopharma channels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Biofidelity social profiles

Digital presence

Biofidelity compliance and trust

Trust signal

Compliance7 records

Biofidelity financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Biofidelity leadership team

Management profile

Number of profiles

Profiles15 records

Biofidelity funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Biofidelity M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biofidelity

What does Biofidelity do?

Biofidelity develops proprietary pyrophosphorolysis-based molecular diagnostic technology sold under the Aspyre® and Enspyre® brands. The company sells research-use reagents (Aspyre Lung Reagents) to laboratories and biopharma companies, operates a CLIA-certified laboratory providing the Aspyre Clinical Test for Lung (a laboratory-developed test for NSCLC biomarker detection from tissue or blood), and licenses Enspyre NGS target enrichment technology to pharma, CROs, and precision medicine developers.

Is Biofidelity a public or private company?

Biofidelity is a private company. It is classified as venture growth investor backed and is currently operating.

When was Biofidelity founded?

Biofidelity was founded in 2019. It employs 11 to 50 people.

Where is Biofidelity based?

Biofidelity is headquartered in Cambridge, United Kingdom, in the Europe region.

How does Biofidelity make money?

Three revenue lines are on record. Clinical Laboratory Testing Services are the primary driver. The others are research Use Only Reagent Sales and licensing and Partnership Revenue.

Who are Biofidelity's main competitors?

Direct peers on record are Exact Sciences, NeoGenomics, Guardant Health, Caris Life Sciences, Personalis and Natera. Broad incumbents are Foundation Medicine (Roche) and Tempus. Emerging players are Resolution Bioscience (Agilent) and Oncocyte.

Does Biofidelity have an API?

No public API is recorded for Biofidelity.

What industry is Biofidelity in?

Biofidelity's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAGAIAI, Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes), with a secondary code of HLAGADAH, Cell-Based & Potency Assays (Bioassays). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireCellCarta Secures Global Exclusivity for Biofidelity's Aspyre® Lung to Advance Targeted Lung Cancer TestingCellCarta and Biofidelity have announced an expanded multi-year global strategic partnership, granting CellCarta global exclusivity to deploy Aspyre® Lung—a targeted genomic test for lung cancer—in clinical trial settings. The assay delivers results in 4 to 5 days with success rates up to 99%, compared to standard NGS testing which can take three weeks or more with a 25% sample failure rate and higher costs. The partnership aims to simplify lung cancer trial execution by enabling sponsors to access targeted testing through a single coordinated provider, reducing operational complexity and barriers to adoption.GenomeWebCellCarta Gains Exclusive Rights to Biofidelity's Aspyre Lung Cancer Assay for Clinical TrialsCellCarta has obtained exclusive global rights to offer Biofidelity's Aspyre Lung assay in clinical trials, expanding a strategic partnership the two companies established last year. The Aspyre Lung assay is a pyrophosphorolysis-based lung cancer mutation detection test targeting 111 mutations in 11 genes relevant to non-small cell lung carcinoma. The deal positions CellCarta as the exclusive clinical trial partner and establishes a coordinated framework for deploying the assay in global clinical trials, with potential for future collaboration on Biofidelity's minimal residual disease technology.PR NewswireBiofidelity and CellCarta partner to deploy Aspyre® Lung in global clinical trialsBiofidelity and CellCarta announced a strategic partnership to deploy Biofidelity's Aspyre® Lung genomic test in global clinical trials, with CellCarta gaining non-exclusive rights to utilize the test for clinical trial enrollment. CellCarta will establish and validate Aspyre Lung in its European laboratories first, followed by US-based facilities, enabling rapid and reliable detection of non-small cell lung cancer biomarkers through a streamlined four-step workflow compatible with existing qPCR platforms. The partnership aligns with both companies' missions to advance precision medicine by providing simplified genomic profiling services to biopharmaceutical companies conducting clinical trials worldwide.Pulse 2.0Biofidelity: Genomic Technology Company Secures $24 Million In FundingBiofidelity completed a $24 million financing round, bringing total funding to $60 million since 2019. The funds will accelerate US commercial and clinical expansion of ASPYRE-Lung, a lung cancer biomarker test, and establish a UK manufacturing facility. The round includes new commitments from current investors.PR NewswireBiofidelity to present ASPYRE®-Lung data at AACR 2024Biofidelity announced that new data from its ASPYRE-Lung product will be presented in three scientific posters, including a Late Breaking Abstract, at the AACR 2024 Annual Meeting in San Diego. The data demonstrates that ASPYRE-Lung can generate clinical reports covering all guideline-recommended NSCLC biomarkers for 98% of samples that failed standard NGS QC testing, addressing a gap affecting patients who would otherwise not receive results to guide therapy selection. The product enables delivery of results within two days, targeting a major challenge where up to 25% of NGS samples fail QC, contributing to inadequate patient care in more than half of lung cancer patients in the US.PR NewswireBiofidelity raises $24 million in new financing to accelerate commercialization and expand product pipelineBiofidelity completed a $24 million financing round, bringing its total funding to $60 million, to accelerate the commercialization of its ASPYRE-Lung test and expand its product pipeline. The capital will fund clinical expansion in the United States and the establishment of a manufacturing facility in the United Kingdom. Investors Agilent Technologies, Octopus Ventures, BlueYard Capital, and Longwall Ventures participated in this latest round.PerscitusllpBiofidelity raises $24 million in new financing to accelerate commercialization and expand product pipelineBiofidelity has completed a $24 million financing round, bringing its total funding to $60 million since its inception in 2019. The company plans to use the capital to expand commercial and clinical operations in the United States for its ASPYRE®-Lung test and to establish a dedicated manufacturing facility in the United Kingdom.FinSMEsBiofidelity Raises $24M in FundingBiofidelity, a genomic technology company, has raised $24 million in funding led by Dr. Barnaby Balmforth with participation from Agilent Technologies, Octopus Ventures, BlueYard Capital, and Longwall Ventures. The company intends to use the capital to accelerate commercial and clinical expansion of its ASPYRE®-Lung test in the United States and establish a dedicated manufacturing facility in the United Kingdom.Business WeeklyBiofidelity raises $24m to fast-track growth and expand pipelineBiofidelity has raised $24 million in new funding to accelerate the commercial adoption of its ASPYRE-Lung diagnostic test and expand its clinical pipeline. The investment, which brings total capital raised since 2019 to $60 million, will also support the establishment of a dedicated manufacturing facility in the UK. Key investors including Agilent Technologies reaffirmed their support, citing confidence in the company's ability to address critical gaps in genomic testing.PR NewswireBiofidelity announces the commercial launch of ASPYRE-Lung in the USBiofidelity announced the commercial launch of ASPYRE-Lung in the US, a novel assay that detects biomarkers for non-small cell lung cancer and delivers results within days of diagnosis at a fraction of the cost of current sequencing tests. The launch addresses a critical gap where 65 percent of lung cancer patients start treatment without recommended biomarker testing due to the lengthy turnaround time of existing solutions. The assay leverages existing laboratory instrumentation to provide comprehensive biomarker results across all guideline-recommended genes for NSCLC, enabling clinicians to offer targeted treatment options more quickly.